N@N

Cephalon (CEPH) Gains As Much As 13.25% After BUYINS.NET Report Predicted On August 30th The Stock Would Rally On Seasonal Stre

^{Published on 2010-09-28 16:40:46, Last Modified on 2010-12-22 18:47:35 - WOPRAI}
 

September 28, 2010 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on August 30th, 2010 stating that Cephalon (NASDAQ: CEPH) was expected to be higher due to seasonal strength in the stock. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?id=122286

The results of the prediction are the following:

Symbol 8/30/2010 Hi Since $Change % High 9/28/2010 $Change % Today

CEPH $57.05 $64.61 $7.56 13.25% $64.02 $6.97 12.22%

By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

Cephalon, Inc. (NASDAQ: CEPH), a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients. The companya�s pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in opioid-tolerant patients. Its products for oncology consist of TREANDA, a bi-functional hybrid cytotoxic; TRISENOX, an intravenous arsenic-based targeted therapy; CEP-701, an oral small molecule tyrosine kinase inhibitor; MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, an anti-fungal product for cancer patients. The company provides its products principally to wholesale drug distributors. It has collaboration agreements with Euroscreen s.a.; Ligand Pharmaceuticals Incorporated; Psychogenics Inc.; and AMBIT Biosciences Inc, as well as a research agreement with Celator Pharmaceuticals Inc. Cephalon, Inc. markets its products primarily in the United States, Europe, the Middle East, and Africa. The company was founded in 1987 and is headquartered in Frazer, Pennsylvania.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net